Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.58
- Piotroski Score 2.00
- Grade Buy
- Symbol (HARP)
- Company Harpoon Therapeutics, Inc.
- Price $23.01
- Changes Percentage (0.09%)
- Change $0.02
- Day Low $22.99
- Day High $23.02
- Year High $23.21
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 08/08/2023
- Fiscal Year End N/A
- Average Stock Price Target $700.00
- High Stock Price Target $700.00
- Low Stock Price Target $700.00
- Potential Upside/Downside N/A
- Consensus Rating Buy
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.53
- Trailing P/E Ratio -15.039215686275
- Forward P/E Ratio -15.039215686275
- P/E Growth -15.039215686275
- Net Income $-67,137,000
Income Statement
Quarterly
Annual
Latest News of HARP
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Solar Orbiter snaps sharpest ever images of the sun
NASA and ESA's Solar Orbiter spacecraft has sent back high-resolution images of the sun's surface, magnetic field, and corona. The images offer detailed insight into the sun's dynamic nature and were ...
By Newsweek | 1 day ago -
Sharpening Knives At Home: A Better Way To Keep Your Blades In Shape
New knife sharpeners for home chefs make it easy to maintain sharp knives without the cost of professional services. Dull knives are dangerous and can be easily sharpened at home with new tools like t...
By Forbes | 1 day ago -
Inflation soars back above Bank of England target in sharpest spike for two years
Consumer price inflation, after hitting a 41-year high in 2022, dropped to 1.7% in September but rose to 2.3% in October due to energy bill hikes. The Bank of England aims to control inflation by adju...
By Yahoo! Finance | 2 days ago
